GPCRs (G-protein-coupled receptors) are seven-transmembrane helix proteins that transduce exogenous and endogenous signals to modulate the activity of downstream effectors inside the cell. Despite the relevance of these proteins in human physiology and pharmaceutical research, we only recently started to understand the structural basis of their activation mechanism. In the period 2008-2011, nine active-like structures of GPCRs were solved. Among them, we have determined the structure of light-activated rhodopsin with all the features of the active metarhodopsin-II, which represents so far the most native-like model of an active GPCR. This structure, together with the structures of other inactive, intermediate and active states of rhodopsin constitutes a unique structural framework on which to understand the conserved aspects of the activation mechanism of GPCRs. This mechanism can be summarized as follows: retinal isomerization triggers a series of local structural changes in the binding site that are amplified into three intramolecular activation pathways through TM (transmembrane helix) 5/TM3, TM6 and TM7/TM2. Sequence analysis strongly suggests that these pathways are conserved in other GPCRs. Differential activation of these pathways by ligands could be translated into the stabilization of different active states of the receptor with specific signalling properties.
and, moreover, provide an important link to our environment as the principal receptors for our senses of vision, smell and taste.
Since 2008, nine active-like structures of GPCRs [five of bovine rhodopsin, two of the human β 2 AR (β 2 adrenergic receptor) and two of the human A 2A R (adenosine A 2A receptor)] have been published. The first structures corresponded to opsin, the ligand-free form of rhodopsin, alone [2] and in complex with a synthetic peptide derived from the Cterminus of the α-subunit of the G-protein (GαCT) [3] . Even though opsin is inactive under physiological conditions, these structures obtained at low pH presented the structural features expected in an active rhodopsin, particularly the large-scale movement of TM (transmembrane helix) 6 [4] [6 Å (1 Å = 0.1 nm) measured at residue 6.33] . However, the lack of the bound agonist precluded any interpretation on how the agonist stabilizes the active form of the protein.
The next breakthrough was the publication of an active-like structure of the β 2 AR [5] . Obtaining this structure required a formidable effort of protein engineering, including post-translational modifications, truncation of flexible termini, creation of T4 lysozyme fusion chimaeras and binding of a specific camelid antibody fragment (nanobody), combined with the use of high-affinity and very-low-off-rate synthetic agonists. Although the structural changes in TM5 and TM7 were remarkably similar to those observed in the structures of opsin, the rearrangement of TM6 was considerably larger (8 Å ). In 2011, two active structures of rhodopsin containing the retinal agonist were published simultaneously. One of them corresponds to the constitutively active mutant E113Q(3.28) [6] (numbers in parentheses refer to the Ballesteros-Weinstein general numbering scheme [7] ) in complex with GαCT, which retains the isomerized retinal in the binding pocket after lightactivation, albeit in a hydrolysed form [6] . In the other, opsin at low pH was soaked in all-trans-retinal, allowing binding of retinal and formation of the covalent Schiff base bond [8] . This structure revealed an unexpected rotation of the polyene chain of the retinal, while a simultaneous rotation of the β-ionone ring maintains the 6-s-cis bond, in agreement with solid-state NMR data that indicate this orientation of the ring in metarhodopsin-II [9] . This rotation of retinal is accompanied by a relaxation from a bent conformation, as observed in the bathorhodopsin and lumirhodopsin states, to a nearly planar relaxed conformation.
This same year, two groups presented structures of the agonist-bound A 2A R. One structure was also obtained through fusion of T4 lysozyme to the third intracellular loop of the receptor plus deletion of the C-terminus [10] , whereas the other [11] was obtained after conformational thermostabilization of the protein [12] . Both structures featured an agonist-induced rearrangement of a cluster of hydrophobic and aromatic residues in the TM3/TM5/TM6 interface near the binding site, similarly to the active structures of β 2 AR and rhodopsin. However, the relocation of TM5 and TM6 are smaller than in active rhodopsin and β 2 AR. These relatively small changes in the cytoplasmic surface of the receptor do not seem to open the crevice necessary for binding of intracellular partners. Thus the agonist-bound A 2A R structures probably resemble a metarhodopsin-I-like intermediate state that has not yet expressed the full conformational changes that allow binding of the G-protein.
Furthermore, 2011 also brought the first crystal structure of a complex between agonist-bound β 2 AR and nucleotidefree G αs protein [13] , stabilized by binding of a nanobody. In this complex, the C-terminus was partially truncated and the N-terminus of the receptor was replaced with T4 lysozyme to facilitate crystal formation. This structure revealed large conformational changes in the receptor, particularly a 14 Å movement at the cytoplasmic end of TM6. Also, it revealed a major rigid-body displacement of the α-helical domain of G αs relative to the Ras-like GTPase domain. The functional significance of this large movement remains to be elucidated [14, 15] .
All of these structures have provided invaluable information that allows us to start piecing together a conserved activation mechanism for GPCRs [16] [17] [18] . However, these activated states have been reached by mechanisms that are far from the natural activation mechanisms. On the other hand, the recently published constitutively active M257Y(6.40) rhodopsin mutant in complex with GαCT [19] is the only active structure obtained with the natural agonist, in this case, all-trans retinal created by the natural process of lightinduced isomerization. Moreover, this structure contains the complete polypeptide including intact post-translational modifications and only three mutations. Importantly, this structure contains all the features of the true active Gprotein-binding state, metarhodopsin-II: the position of retinal and translocation of its β-ionone ring with respect to ground state rhodopsin are in good agreement with solid-state NMR measurements on the active state [9] ; the covalent Schiff base link can be identified as the 15-antibond conformation, a further defining characteristic of fully activated metarhodopsin-II [20] ; and the conformational changes of TM5 and TM6 are in very good agreement with DEER (double electron-electron resonance) spectroscopy [21] and cross-linking experiments [4] , resulting in the opening of a specific binding interface to the C-terminus of the G-protein. Thus we conclude that our structure indeed closely resembles the fully activated receptor metarhodopsin-II, representing one of the best models of an activated GPCR. Together with the wealth of biochemical, biophysical and spectroscopic data on rhodopsin activation and the availability of structures from several activation states, the rhodopsin system now provides a unique framework on which to study the conserved aspects of GPCR activation.
Activation pathways in GPCRs
The crystal structures of inactive, intermediate and active states represent snapshots that can be put together to recreate the dynamic processes of rhodopsin activation. Specifically, by comparing these structures, we can infer how the local structural changes induced by retinal isomerization are translated into the larger-scale rearrangements. In summary, in the dark state, retinal is tightly packed in the binding pocket (Figure 1, left) . During formation of the lumirhodopsin state, retinal isomerization translates first [22] into an increase in the contacts between retinal and residues in TM5/TM6 and in small conformational changes in TM2/TM7 (Figure 1 , centre). In the transition to metarhodopsin-II, there is a decrease in the contacts between retinal and TM3, primarily at Glu 122 , and an increase from residues of ecl2 (extracellular loop 2), TM5 (Met 207 ) and TM6 (Tyr 286 ) (Figure 1, right) . Thus, upon isomerization, retinal moves away from TM3 and towards ecl2 and the TM5/TM6 interface. We suggest that these new contacts trigger specific activation pathways through these helices [23] [24] [25] . In the following sections, we describe the conformational changes associated with each of these pathways. Furthermore, by analysing the patterns of sequence conservation, we can infer how these mechanisms may be conserved in other GPCRs. in metarhodopsin-II, retinal moves further towards TM5/TM6 and ecl2, and away from TM3. These ligand-induced local structural changes trigger specific activation pathways through these helices.
Ligand-induced structural changes in TM5
Retinal . Solidstate NMR confirmed the role of Tyr 223(5.57) in rhodopsin activation and its stabilizing effect on the metarhodopsin-II state [26] . Also, FTIR (Fourier-transform infrared) analysis of azido-labelled rhodopsin suggests that this conformational change is already starting to appear in the metarhodopsin-I state [27] .
The residues responsible for transmitting retinal isomerization into conformational changes in TM5 are not conserved throughout GPCRs. For instance, the sequence analysis of human Class A (or rhodopsin-like) GPCRs (performed with the program GMoS, available at http://lmc.uab.cat/gmos/) shows that position 5.42 is a bulky hydrophobic residue (leucine/isoleucine/valine/methionine) in ∼40 % and a small/polar residue (serine/threonine/alanine/glycine/ asparagine/cysteine/aspartate) in ∼37 % of the sequences. However, this position is indeed conserved within some of the major subfamilies. For instance, 100 % of human rhodopsins possess a bulky hydrophobic residue, or 100 % of human amine receptors (excluding trace amine receptors) feature a small polar residue at this position. Despite these differences, weakening of the TM3/TM5 interface as a step in activation has been proposed for other GPCRs, such as β 2 AR [5] and histamine H 1 receptor [25] . Thus, although the precise mechanism of ligand-induced triggering of this activation pathway through TM5 is family-specific, it seems to be translated into a conserved set of rearrangements in TM5 that involve highly conserved residues in Class A GPCRs, as Pro5.50 and a bulky hydrophobic residue (isoleucine/valine/leucine) at position 3.40 (Figure 2 , red arrow).
Ligand-induced structural changes in TM6
The movement of the β-ionone ring towards the TM5/TM6 interface during the dark rhodopsin-lumirhodopsinmetarhodopsin-II transition is followed by the side chain of Trp 265(6.48) , which does not change rotamer during this process. Transition to the metarhodopsin-II state also translates into an increased contact between the ligand and Tyr 268(6.51) , which results from a change in the side-chain conformation of the residue and a rigid-body rotation of TM6 of ∼ 45
• at this position. Thus TM6 seems to be locked in an inactive conformation by 11-cis-retinal, and isomerization of the ligand and relocation of the β-ionone ring creates some space that releases the extracellular side of TM6, which rotates following the ligand, primarily due to the contacts between retinal and Trp 265 (6.48) and Tyr 268 (6.51) . This rigid-body rotation is amplified along this long helix, resulting in the large conformational rearrangement at the cytoplasmic side of TM6 [6] (Figure 2, green arrow) . This conformational change also starts to appear already in the metarhodopsin-I state [27] .
The large-scale movement of TM6 has been characterized in several GPCRs and also observed directly in β 2 AR [5, 13] and, to a lesser extent, A 2A R [10, 11] . In this case, the residues responsible for transmitting the relatively small changes in the binding pocket to the cytoplasmic side of the helix, Trp 265(6.48) and Tyr 268(6.51) , are highly conserved in Class A GPCRs. Thus the mechanism of stabilization of the active conformation of TM6 by direct contact between the ligand and the residues at positions 6.48 and 6.51 is likely to be a common feature of Class A GPCR activation. Without bound agonists, the residues at positions 6.48 and 6.51 are not fixed in an empty pocket, and therefore the extracellular side of TM6 can potentially fluctuate between different conformations. Although different sets of interhelical interactions are likely to provide additional stability to an inactive-like conformation of the helix, this decreased conformational stability is possibly related to constitutive activity. Consequently, inverse agonists may stabilize the inactive conformation of the receptor by, among other mechanisms, locking TM6 in an inactive-like conformation through interactions with residues at positions 6.48 and 6.51.
Ligand-induced structural changes in TM2 and TM7
In [28] , and may be stabilized by a water molecule [22] . Mutations in this GGXTTT motif affect retinal binding [29] and increase constitutive activity of the receptor [29, 30] , leading to the development of congenital stationary night blindness [31] .
Structurally, transition to lumirhodopsin results in a marked change in the backbone of TM2 around the Gly 89(2.56) -Gly 90(2.57) motif [22] . These preliminary changes are notably amplified in the transition to the metarhodopsin-II state. Rearrangement of the intrahelical hydrogen-bond network in the GGXTTT motif, assisted by the change of conformation of Thr 94(2.61) , and possibly relocation of a water molecule, results in a small rearrangement of TM2 away from the transmembrane bundle core. This movement is accompanied by a similarly modest relocation of TM3 and the larger-scale movement of TM6 at Trp 265(6.48) , also away from the transmembrane bundle core. As a result, the packing between TM2, TM3, TM6 and TM7 weakens, and a pocket connecting the ligand-binding site to the cytoplasmic side of the transmembrane bundle is created. On one hand, this allows the water molecules in the cluster between TM2, TM3, TM6 and TM7 (Figure 2 , cyan spheres) to relocate towards the cytoplasmic side of the transmembrane bundle to engage in a new hydrogen-bond network between highly conserved residues and the C-terminal G-protein peptide [6] . On the other hand, relocation of these water molecules results in the rearrangement of the intrahelical hydrogen-bond network in TM7, which is translated into a noticeable structural change (Figure 2, blue arrow) , where the 3.10-helix segment between Lys 296(7.43) and Ala 299(7.46) [32] becomes more α-helical. This last change is key to position Tyr 306(7.53) towards the protein core, where it participates in the intrahelical interactions that stabilize the active state.
Although the above activation mechanism involving the GGXTTT motif is specific to rhodopsin, this region is key for ligand-induced activation in several GPCRs [33, 34] . Interestingly, two indel events in TM2 that help to trace the evolution of Class A GPCRs have been proposed to result in different structural motifs [35] . The GGXTTT sequence at 2.56-2.61, albeit highly conserved in rhodopsin vertebrate type 1 GPCRs, is strongly divergent in other Class A GPCRs. For instance, there are several proline residues at the 2.57, 2.58, 2.59 and 2.60 positions with different patterns of conservation in different subfamilies [28] . In the currently available crystal structures, a variety of sequence motifs in this region stabilize different local structures that are key to shape the binding pocket. Also, the cluster of water molecules in the TM2/TM3/TM6/TM7 interface have been proposed to be present in other Class A GPCRs, and participate in the mechanism of activation [36] [37] [38] . Thus this activation pathway through TM7, initiated at TM2, is probably conserved in other GPCRs.
In summary, retinal isomerization in rhodopsin triggers (or stabilizes) a series of local structural changes that are amplified along the dynamic process of receptor activation into the larger rearrangements observed in the active crystal structures. These structural changes can be categorized into three intramolecular activation pathways through TM5/TM3 (Figure 2 , red arrow), TM6 (Figure 2 , green arrow) and TM7/TM2 (blue arrow). Analysis of the patterns of sequence conservation in Class A GPCRs strongly suggests that these pathways are conserved throughout the family. We hypothesize that ligands may activate differently these activation pathways. For instance, although a full agonist (as all-trans-retinal) probably triggers all of them, a partial agonist might activate preferentially only two of them. By this relatively simple mechanism, ligands with different chemical properties would be able to stabilize slightly different active states of the receptor with specific signalling properties.
